|Bid||1.3500 x 4000|
|Ask||1.6000 x 1000|
|Day's Range||1.3200 - 1.3928|
|52 Week Range||0.7000 - 4.7900|
|Beta (3Y Monthly)||3.91|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary Aegerion Pharmaceuticals, today announced its observance of World Lipodystrophy Day. World Lipodystrophy Day is an international campaign designed to raise awareness about the impact of living with lipodystrophy. Interim Chief Executive Officer Ben Harshbarger said, "We stand with the patient community in honor of World Lipodystrophy Day with a mission of increasing awareness and diagnosis of this serious rare disease.
Novelion Therapeutics Inc is a biopharmaceutical company. Novelion Therapeutics Inc had annual average EBITDA growth of 2.50% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with NVLN.
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.03. Earnings, adjusted for non-recurring costs and stock option expense, were 15 cents per share. The retinal ...
Company achieves FY 2018 total net revenues of $130.4 million FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and CAMBRIDGE, Mass.,.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards.
HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...
Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”), has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. (“Recordati”) for the commercialization of JUXTAPID® (lomitapide) in Japan. The agreement includes exclusive rights in Japan for Recordati to commercialize JUXTAPID for the current approved indication, homozygous familial hypercholesterolemia (HoFH), and Aegerion grants Recordati an exclusive right of first negotiation for product commercialization in Japan of any potential new indications that may be developed by Aegerion.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / Shares of Novelion Therapeutics and Revance Therapeutics were both soaring on Tuesday on separate developments. Novelion saw gains as it was revealed that biotech focused venture capital firm Healthcare Value Capital sent a letter demanding exploration of strategic alternatives, while Revance Therapeutics soared on news that its Botox rival succeeds in late-stage trial and that it had reached an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Novelion Therapeutics Inc. shares were up 32.65% yesterday at the close on almost 17.5 million shares traded.
Novelion revealed through an amendment to a SEC 13-D filing that biotech-focused venture capital firm Healthcare Value Capital sent a letter to Novelion's board urging the exploration of strategic alternatives. In the letter signed by Joseph Riccardo, managing member at Healthcare Value Capital, the firm accused Novelion of allowing costs to spiral out of control.
ReShape announced several encouraging developments including data regarding the treatment of type 2 diabetes mellitus but saw its shares sold off. Novelion Therapeutics Inc. shares were up 7.61% at the close yesterday with roughly 2% more seen in after-hours trading in gains. There was no significant news from the company yesterday but it was last week that the biopharmaceutical company said that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately.
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...
Novelion Therapeutics Inc. (NVLN), today announced that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately. Jeffrey Hackman resigned as interim CEO to pursue another opportunity and will stay with the Company in a transitional role until November 30, 2018. Dr. Corrigan commented, “In the past year, we have made substantial progress in the turnaround of Novelion, and on behalf of the Board of Directors, I’d like to thank Jeff for his dedication to this mission.
VANCOUVER, British Columbia, Nov. 09, 2018 -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / While shares of healthcare company Perrigo Company were tanking after reporting third quarter financial results, Novelion Therapeutics, which is developing ...
Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”), after soliciting third party lenders, has entered into a new secured financing facility with certain funds managed by Athyrium Capital Management (Athyrium) and Highbridge Capital Management, LLC (Highbridge) (the “New Lenders”). The facility consists of $50.0 million in new secured first lien term loans that were funded to Aegerion in cash and $22.5 million of new secured term loans that were used, on behalf of Aegerion, to retire an equal amount of Aegerion’s 2% convertible notes due August 2019, at par, held by certain funds managed by each of Athyrium and Highbridge.
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.67. Losses, adjusted for amortization costs and non-recurring costs, came to 59 cents per share. The retinal ...
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic ...